Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Valvular Heart Disease

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    March 2026
  1. PETERSEN JK, Schops LB, Melchior S, Baker K, et al
    Admission with heart failure or atrial fibrillation before mitral valve surgery and associated outcomes.
    Am Heart J. 2026 Mar 2:107397. doi: 10.1016/j.ahj.2026.107397.
    PubMed     Abstract available


    February 2026
  2. ROSSANO J, Canter C, Wolf C, Favatella N, et al
    Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial.
    Am Heart J. 2026;292:107283.
    PubMed     Abstract available


    January 2026
  3. WANG C, Liu Z, Li Z, Yan X, et al
    STrategies for Antithrombotic tRreatment following Transcatheter Edge-to-Edge Repair in patients with severe mitral regurgitation: rationale and design of STAR-TEER trial.
    Am Heart J. 2026 Jan 28:107362. doi: 10.1016/j.ahj.2026.107362.
    PubMed     Abstract available


  4. VEKSTEIN AM, Salah HM, Stebbins A, Wegermann Z, et al
    Early Outcomes of Off-Label Transcatheter Tricuspid Valve Repair/Replacement in the STS/ACC TVT Registry.
    Am Heart J. 2026 Jan 19:107355. doi: 10.1016/j.ahj.2026.107355.
    PubMed     Abstract available


  5. MAYOURIAN J, Sleeper LA, Diwanji V, Geva A, et al
    Artificial intelligence-enabled electrocardiogram guidance for pulmonary valve replacement timing in repaired tetralogy of Fallot.
    Am Heart J. 2026;291:153-161.
    PubMed     Abstract available


    December 2025
  6. HARVEY JE 3RD, Ryan M, Gunnarsson C, Chikermane S, et al
    Incremental cost of complications after TAVR and SAVR in contemporary clinical practice.
    Am Heart J. 2025;290:278-287.
    PubMed     Abstract available


  7. WEI C, Sharma P, Paranjpe I, Heidenreich PA, et al
    Balancing cost and care: Analyzing commercial pricing for TAVR and SAVR.
    Am Heart J. 2025;290:1-5.
    PubMed     Abstract available


    November 2025
  8. VAN DEN ENDEN AJM, van den Dorpel MMP, Mondellini GM, Mattace-Raso AM, et al
    Immediate changes in Left Ventricular Cardiac Mechanics following Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis - an In-Vivo Pressure-Volume Analysis study.
    Am Heart J. 2025 Nov 13:107302. doi: 10.1016/j.ahj.2025.107302.
    PubMed     Abstract available


  9. RAVI SN, O'Shea M, Baqal O, Fatunde OA, et al
    The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy.
    Am Heart J. 2025;289:28-37.
    PubMed     Abstract available


  10. TOBE A, van Royen N, Amat-Santos IJ, Hudec M, et al
    Win ratio analysis of the LANDMARK trial.
    Am Heart J. 2025;289:1-5.
    PubMed     Abstract available


    October 2025
  11. HEMELRIJK K, Jimenez-Diaz VA, Vilchez JP, Oteo JF, et al
    Rationale and design of REAC-TAVI 2: single antiplatelet treatment with ticagrelor versus aspirin after transcatheter aortic valve implantation.
    Am Heart J. 2025 Oct 31:107293. doi: 10.1016/j.ahj.2025.107293.
    PubMed     Abstract available


  12. OVERDUIN DC, van Ginkel DJ, Dubois C, Lesizza P, et al
    Routine versus selective protamine administration to reduce bleeding after TAVI: Rationale and Design of the POPular ACE TAVI trial.
    Am Heart J. 2025 Oct 31:107296. doi: 10.1016/j.ahj.2025.107296.
    PubMed     Abstract available


    September 2025
  13. TOMII D, Alaour B, Heg D, Okuno T, et al
    Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves in Patients with Excessive Aortic Valve Cusp Calcification.
    Am Heart J. 2025 Sep 18:S0002-8703(25)00333-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    August 2025
  14. PARK HS, Suh CH, Ahn JM, Kang DY, et al
    Effect of Cerebral Embolic Protection Device on New Cerebral Embolism During Transcatheter Aortic Valve Replacement: A Prospective Sentinel Registry.
    Am Heart J. 2025 Aug 13:S0002-8703(25)00296-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    July 2025
  15. JORGENSEN TH, Thyregod HGH, Blankenberg S, Leon M, et al
    The Low-Risk TAVR Trials - A Critical Appraisal of the Current Landscape.
    Am Heart J. 2025 Jul 29:S0002-8703(25)00288-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  16. VAKILPOUR A, Levin MG, Anyanwu EC, Denduluri S, et al
    Referral patterns and clinical outcomes in patients with severe aortic stenosis: A multicenter cohort study.
    Am Heart J. 2025 Jul 22:S0002-8703(25)00223-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  17. MOHAMMADNIA N, Vestjens LTW, Craig NJ, Tijssen JGP, et al
    The Effects of Low-Dose Colchicine on the Progression of Aortic Valve Stenosis: Rationale, Design, and Baseline Characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial.
    Am Heart J. 2025 Jul 12:S0002-8703(25)00219-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    June 2025
  18. KRASNIQI L, Skovbo JS, Hallas PJ, Brandes PA, et al
    Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.
    Am Heart J. 2025 Jun 13:S0002-8703(25)00194-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    April 2025
  19. JIANG Z, Chang S, Tao L, Luo J, et al
    The randomized controlled trial to compare temporary permanent pacemaker versus temporary pacemaker in patients with conduction block after transcatheter aortic valve replacement: rationale and design of the RECOVER trial: Randomized trial for Tempora
    Am Heart J. 2025 Apr 19:S0002-8703(25)00135-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  20. GRBAC AJ, Lee MGY, Chye D, Zhou JY, et al
    MANAGEMENT OF ASYMPTOMATIC SEVERE AORTIC STENOSIS: A CRITICAL REVIEW OF GUIDELINES AND CLINICAL OUTCOMES.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00128-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  21. HORN N, Gartner L, Rastan AJ, Andrasi TB, et al
    Effects of a preoperative psychological expectation-focused intervention in patients undergoing valvular surgery - the randomized controlled ValvEx (valve patients' expectations) study.
    Am Heart J. 2025;282:156-169.
    PubMed     Abstract available


    February 2025
  22. ANDO T, Nazif T, Briasoulis A, Afonso L, et al
    Clinical Outcomes of Direct Oral Anticoagulant Versus Warfarin After Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00057-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  23. LEENING MJG, Khan CF, Zhu F, Singh SS, et al
    Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.
    Am Heart J. 2025 Feb 18:S0002-8703(25)00040-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  24. JORGENSEN TH, Thyregod HGH, Savontaus M, Bleie O, et al
    Transcatheter or Surgical Aortic Valve Replacement in patients with Severe Aortic Stenosis Aged 70 Years or Younger - a NOTION-2 sub-study.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00034-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  25. NAKASE M, Tomii D, Maznyczka A, Heg D, et al
    Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction.
    Am Heart J. 2025;280:18-29.
    PubMed     Abstract available


    January 2025
  26. BALDI C, Maio MD, Esposito L, Bellino M, et al
    How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry.
    Am Heart J. 2025 Jan 27:S0002-8703(25)00011-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  27. SHECHTER A, Gupta A, Kaewkes D, Taheri H, et al
    Implications of an Off-Hours Setting in Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation.
    Am Heart J. 2025 Jan 2:S0002-8703(24)00341-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    December 2024
  28. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    November 2024
  29. REDDY KP, Shultz K, Eberly LA, Khatana SAM, et al
    Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population.
    Am Heart J. 2024 Nov 27:S0002-8703(24)00302-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  30. ABRAHAM B, Suppah M, Farina J, Botros M, et al
    Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Nov 12:S0002-8703(24)00295-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  31. IANNOPOLLO G, Cocco M, Leone A, Sacca S, et al
    TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery.
    Am Heart J. 2024 Nov 4:S0002-8703(24)00281-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    October 2024
  32. THURAIAIYAH J, Jorgensen TH, Jensen JM, Fuchs A, et al
    Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves - The NOTION-4 trial: Anti-thrombotic therapy and TAV-HALT.
    Am Heart J. 2024 Oct 5:S0002-8703(24)00264-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    August 2024
  33. SOH CH, Wright L, Baumann A, Seidel B, et al
    Use of artificial intelligence-guided echocardiography to detect cardiac dysfunction and heart valve disease in rural and remote areas: Rationale and design of the AGILE-echo trial.
    Am Heart J. 2024;277:11-19.
    PubMed     Abstract available


  34. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  35. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  36. TERKELSEN CJ, Thim T, Freeman P, Dahl JS, et al
    Randomized comparison of TAVI valves: The Compare-TAVI trial.
    Am Heart J. 2024;274:84-94.
    PubMed     Abstract available


    July 2024
  37. BUTT JH, Yafasova A, Thein D, Begun X, et al
    Burden of Hospitalization During the First Year Following Transcatheter and Surgical Aortic Valve Replacement.
    Am Heart J. 2024 Jul 29:S0002-8703(24)00180-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  38. ELLFORS E, Dismorr M, Ruck A, Settergren M, et al
    Predicted prosthesis-patient mismatch and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00175-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  39. PERSITS I, Mirzai S, Sarnaik KS, Volk MC, et al
    Sarcopenia and Frailty in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00173-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    June 2024
  40. ABOU-KARAM R, Tanguturi V, Cheng F, Elmariah S, et al
    Trial Designs A44002PZS Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: Rationale, design, and methods of the randomized controlled DETECT AS Trial.
    Am Heart J. 2024 Jun 29:S0002-8703(24)00163-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  41. MIYAWAKI N, Ishizu K, Shirai S, Miyahara K, et al
    Impact of the Clinical Frailty Scale on Long-term Outcomes After Transcatheter Aortic Valve Implantation.
    Am Heart J. 2024 Jun 12:S0002-8703(24)00139-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  42. BRUNO F, Rampone JM, Islas F, Gorla R, et al
    Echocardiographic and clinical features of patients developing prosthesis-patient mismatch after TAVR: insights from the Recovery TAVR registry.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00137-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    May 2024
  43. LUPU L, Haberman D, Chitturi KR, Wermers JP, et al
    Overview of 2024 FDA Advisory Panel Meeting on the TriClip Transcatheter Tricuspid Valve Repair System.
    Am Heart J. 2024 May 29:S0002-8703(24)00126-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  44. RICHARDSON C, Gilbert T, Aslam S, Brookes CL, et al
    Rationale and design of the Early valve replacement in severe ASYmptomatic Aortic Stenosis Trial.
    Am Heart J. 2024 May 29:S0002-8703(24)00128-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  45. GUO Y, Liu X, Li R, Ng S, et al
    Comparison of Down Sizing Strategy (HANGZHOU Solution) and Standard Annulus Sizing Strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial.
    Am Heart J. 2024 May 1:S0002-8703(24)00098-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    April 2024
  46. ETIWY M, Flannery LD, Li SX, Morrison FJ, et al
    Examining Lack of Referrals to Heart Valve Specialists as Mechanisms of Potential Underutilization of Aortic Valve Replacement.
    Am Heart J. 2024 Apr 13:S0002-8703(24)00093-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    March 2024
  47. KIM M, Ahn JM, Kang DY, Kim MJ, et al
    Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial.
    Am Heart J. 2024;269:167-178.
    PubMed     Abstract available


    February 2024
  48. ZHANG J, Kong XQ, Gao XF, Chen J, et al
    Transfemoral transcatheter aortic valve replacement with VitaFlow(TM) valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial.
    Am Heart J. 2024 Feb 25:S0002-8703(24)00049-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  49. PREGOWSKI J, Pracon R, Mioduszewska A, Skowronski J, et al
    Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions: Design and rationale of the STOP CLOT Trial.
    Am Heart J. 2024 Feb 22:S0002-8703(24)00043-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  50. KEDHI E, Rroku A, Hermanides RS, Dambrink JH, et al
    TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention versus Conventional Surgical Aortic Valve Replacement and Coronary Bypass Grafting for Treatment of Patients with Aortic Valve Stenosis and M
    Am Heart J. 2024 Feb 1:S0002-8703(24)00019-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    January 2024
  51. JAMMOUL N, Dupasquier V, Akodad M, Meunier PA, et al
    Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial.
    Am Heart J. 2024 Jan 20:S0002-8703(24)00014-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    December 2023
  52. HEGEMAN RRMJJ, van Ginkel DJ, Langle S, Timmers L, et al
    Preoperative CT-imaging with patient-specific computer simulation in transcatheter aortic valve implantation: Design and rationale of the GUIDE-TAVI trial.
    Am Heart J. 2023 Dec 30:S0002-8703(23)00360-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  53. GENEREUX P, Schwartz A, Oldemeyer B, Cohen DJ, et al
    Design and Rationale of the Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: The EARLY TAVR Trial.
    Am Heart J. 2023 Dec 4:S0002-8703(23)00326-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  54. SEVERINSEN T, Thune JJ, Gudmundsdottir HL, Vissing CR, et al
    Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.
    Am Heart J. 2023;266:198-200.
    PubMed     Abstract available


    November 2023
  55. KIM M, Choi JH, Kim HK, Kim HL, et al
    Effects of Intensive Blood Pressure Control on Left Ventricular Hypertrophy in Aortic Valve Disease.
    Am Heart J. 2023 Nov 23:S0002-8703(23)00321-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  56. STRANGE JE, Nouhravesh N, Schou M, Christensen DM, et al
    High-risk admission prior to transcatheter aortic valve replacement and subsequent outcomes: Preceding events and outcomes after TAVR.
    Am Heart J. 2023 Nov 14:S0002-8703(23)00311-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    October 2023
  57. BARON SJ, Ryan MP, Chikermane SG, Thompson C, et al
    Long-Term Risk of Reintervention after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2023 Oct 21:S0002-8703(23)00296-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    August 2023
  58. DODGSON CAS, Beitnes JO, Klove SF, Herstad J, et al
    An investigator-sponsored pragmatic randomised controlled trial of AntiCoagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation - Rationale and design of ACASA-TAVI: Blinded outcome adjudication.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00208-9. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  59. L'HOYES W, Robyns T, Moura-Fereira S, De Meester P, et al
    Effectiveness of the Risk Stratification Proposed by the 2022 European Heart Rhythm Association Expert Consensus Statement on Arrhythmic Mitral Valve Prolapse.
    Am Heart J. 2023 Aug 16:S0002-8703(23)00201-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  60. SOLOMON MD, Tabada G, Sung SH, Allen A, et al
    Physician Assessment of Aortic Stenosis Severity, Quantitative Parameters, and Long-Term Outcomes: Results from the KP-VALVE Project.
    Am Heart J. 2023 Aug 6:S0002-8703(23)00182-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    July 2023
  61. KALMUCKI P, Lipiecki J, Witte KK, Goldberg SL, et al
    Percutaneous mitral annuloplasty with the Carillon device: outcomes in proportionate and disproportionate functional mitral regurgitation.
    Am Heart J. 2023 Jul 27:S0002-8703(23)00181-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    June 2023
  62. SEGUCHI M, Aytekin A, Steiger L, Nicol P, et al
    Near-infrared Spectroscopy-Intravascular Ultrasound to Improve Assessment of Coronary Artery Disease Severity in Patients Referred for Transcatheter Aortic Valve Implantation (The IMPACTavi registry): Design and Rationale.
    Am Heart J. 2023 Jun 12:S0002-8703(23)00159-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  63. KIRMANI S, Woodard PK, Shi L, Hamza TH, et al
    Cardiac Imaging and Biomarkers for Assessing Myocardial Fibrosis in Children with Hypertrophic Cardiomyopathy.
    Am Heart J. 2023 Jun 12:S0002-8703(23)00160-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  64. SHECHTER A, Koren O, Skaf S, Makar M, et al
    Transcatheter Edge-to-Edge Repair for Chronic Functional Mitral Regurgitation in Patients with Very Severe Left Ventricular Dysfunction.
    Am Heart J. 2023 Jun 3:S0002-8703(23)00138-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  65. MEWTON N, Donal E, Picard F, Derimay F, et al
    Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.
    Am Heart J. 2023 Jun 2:S0002-8703(23)00137-0. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  66. RYMER JA, Sun JL, Chiswell K, Cohen D, et al
    Variation in resource utilization and mortality among patients with varying MR type and severity.
    Am Heart J. 2023;260:44-57.
    PubMed     Abstract available


    May 2023
  67. BEGUN X, Butt JH, Kristensen SL, Weeke PE, et al
    Patient Characteristics and Long-term Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation in a Failed Surgical Prosthesis versus in a Native Valve: A Danish nationwide study.
    Am Heart J. 2023 May 11:S0002-8703(23)00118-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    April 2023
  68. LAURIDSEN MD, Valentin JB, Strange JE, Jacobsen PA, et al
    Mortality in patients with chronic obstructive pulmonary disorder undergoing transcatheter aortic valve replacement: The importance of chronic obstructive pulmonary disease exacerbation.
    Am Heart J. 2023;262:100-109.
    PubMed     Abstract available


  69. COISNE A, Aghezzaf S, Butruille L, Woitrain E, et al
    Incidence, Source, and Prognostic Impact of Major Bleeding Across the Spectrum of Aortic Stenosis.
    Am Heart J. 2023 Apr 24:S0002-8703(23)00099-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  70. DEMIREL C, Tomii D, Heg D, Okuno T, et al
    Incidental detection of malignancy during pre-procedural workup for transcatheter aortic valve implantation: a longitudinal cohort study.
    Am Heart J. 2023 Apr 1:S0002-8703(23)00072-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    October 2021
  71. ANANTHAKRISHNA R, Lee SL, Foote J, Sallustio BC, et al
    Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).
    Am Heart J. 2021;240:101-113.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Valvular Heart Disease is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum